Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer response to questions on M&A -> add value to company

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Oct 21, 2022 1:11pm

115 Views

Post# 35039365

RE:RE:RE:RE:RE:RE:RE:RE:RE:Pfizer response to questions on M&A -> add value to company

Noteable wrote: Well that "bunny" opinion is perhaps way out in "left field" since it has repeatedly been stated on this message board that an acquisition by Big Pharma north of US$8 Billion is well within reach and that the two new ONCY board members were tasked with reaching this objective.

We both agree. Have a great weekend

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta